We are pleased to share the webinar organized by the IRDiRC member, Rare Diseases International (RDI) – “From Grassroots to Global: Growing Momentum towards the WHA Resolution on Rare Diseases”. […]
Read More
Medicines Reimagined – The International Drug Repurposing Conference 2025 (#iDR25) hosted by REMEDi4ALL and Beacon aims to unlock the full potential of medicines by driving innovation for patient benefit. This global event […]
Read More
Fondazione Telethon announced that it has submitted the Marketing Authorization Application (MAA) for the gene therapy – etuvetidigene autotemcel – for the treatment of patients with Wiskott-Aldrich Syndrome (WAS), a rare genetic disease […]
Read MoreHosted by the BLACKSWAN Foundation, the International Rare Diseases Research Consortium (IRDiRC) and the European Rare Diseases Research Alliance (ERDERA), the RE(ACT) Congress & IRDiRC Conference offers a unique opportunity […]
Read More
AFM-Téléthon is launching its 2025 calls for proposals to support international research on neuromuscular disorders and rare genetic diseases. These calls are open to both French and international teams, offering […]
Read More
New funding opportunity from the US National Institutes of Health (NIH) – PAR-25-122: Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed) The purpose of […]
Read More
Exciting news from the IRDiRC PACC member EURORDIS! The Rare Barometer survey on the impact of rare diseases on daily life is now open. Open worldwide and available in 25 […]
Read More“Earlier, faster and more accurate diagnosis” We are delighted to share the results of the the recent Rare Barometer survey, developed by the IRDiRC PACC member organization EURORDIS-Rare Diseases Europe, […]
Read More
IRDiRC announces the launch of a new paper on “Newborn screening in Mexico and Latin America: present and future”, part of the Newborn Screening Initiative Real-World Applications and Technologies special […]
Read More
The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for fiscal year (FY) 2025 to support clinical trials for rare […]
Read More